CAS 1258861-20-9|4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide|LY2940680|4-fluoro-N-methyl-N-{1-[4-(2-methylpyrazol-3-yl)phthalazin...

General Information

Structure

Molecular Formula

C₂₆H₂₄F₄N₆O

Molecular Mass

512.5019728

Exact Mass

512.1947723

Charge

InChI

InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3

InChIKey

SZBGQDXLNMELTB-UHFFFAOYSA-N

Canonic Smiles

Fc1ccc(c(c1)C(F)(F)F)C(=O)N(C1CCN(CC1)c1nnc(c2c1cccc2)c1ccnn1C)C

Isomeric Smiles

c1(nnc(c2c1cccc2)N1CCC(CC1)N(C)C(=O)c1c(cc(cc1)F)C(F)(F)F)c1ccnn1C

Calculated Properties

JChem

H Acceptors

H Donor

LogD (pH = 5.5)

3.970506

LogD (pH = 7.4)

3.9770596

Log P

3.9771438

Molar Refractivity

145.0847

Polarizability

50.097492

Polar Surface Area

67.15

Rotatable Bonds

Lipinski's Rule of Five

false

Data Source

Commercial Catalog

Academic Data

Data Source

Names and Identifiers

IUPAC name

4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide

Synonyms

LY2940680

IUPAC Traditional name

4-fluoro-N-methyl-N-{1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide

Names and Identifiers

Registration numbers

PubChem SID

162038053

PubChem CID

49848070

CAS Number

1258861-20-9

Registration numbers

Properties

Product Information

Salt Data

Free Base

Safety Information

Storage Condition

-20°C

Pharmacology Properties

Target

Hedgehog

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

References

PubChem Literature

From Data Sources

• Redmond EM et al. Expert Opin Investig Drugs, 2011, 20(12),1649-1664.

• Mark H. Bender, Cancer Research, 2011, Volume 71, Issue 8, Supplement1

References

Bioactivity

PubChem BioAssay

Bioactivity

Navigation

General Information

Calculated Properties

• RDKit

• JChem

Data Source

• Commercial Catalog

• Academic Data

Names and Identifiers

• IUPAC name

• Synonyms

• IUPAC Traditional name

Registration numbers

• PubChem SID

• PubChem CID

• CAS Number

Properties

• Product Information

• Safety Information

• Pharmacology Properties

• Selleck Chemicals

• PubChem Literature

• From Data Sources

Bioactivity

• PubChem BioAssay

Commercial Catalog

Academic Data

IUPAC name

4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide

IUPAC Traditional name

4-fluoro-N-methyl-N-{1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide

PubChem SID

162038053

PubChem CID

49848070

CAS Number

1258861-20-9

Product Information

Salt Data

Free Base

Safety Information

Storage Condition

-20°C

Pharmacology Properties

Target

Hedgehog

Selleck Chemicals

S2157

Biological Activity

Description

LY2940680 binds to the Smo receptor and potently inhibits Hh signaling.

Targets

Smo

IC₅₀

In Vitro

LY2940680 inhibits cancer growth in cell lines containing a mutation in the gene encoding Smoothened that researchers had previously observed in patient with cancer who developed resistance to vismodegib. ^[1]

In Vivo

LY2940680 has excellent pharmacokinetic properties in rodent and non-rodent species. LY2940680 administrated orally treats Ptch^+/- p53^-/- transgenic mice which spontaneously develop medulloblastoma, produces remarkable efficacy and significantly improves their survival. LY2940680 reveals rapid kinetics of anti-tumor activity through magnetic resonance imaging of these mice, and LY2940680 induces Caspase-3 activity and reduces proliferation by immunohistochemistry analysis of medulloblastoma tumors. LY2940680 inhibits Hh regulated gene expression in the subcutaneous xenograft tumor stroma and produces significant anti-tumor activity. ^[2]

Clinical Trials

LY2940680 is currently being tested in phase 1 trials for people with a range of solid tumors.

Features

Combination Therapy

Description

LY2940680 inhibits the functional activity of resistant Smo mutant (D473H) produced by treatment with GDC-0449 (a Smo antagonist). sup>[2]

References

[1] Redmond EM et al. Expert Opin Investig Drugs, 2011, 20(12),1649-1664.

[2] Mark H. Bender, Cancer Research, 2011, Volume 71, Issue 8, Supplement1

From Data Sources

• Redmond EM et al. Expert Opin Investig Drugs, 2011, 20(12),1649-1664.

• Mark H. Bender, Cancer Research, 2011, Volume 71, Issue 8, Supplement1

Molecule

ID:73133

Biological Activity

Combination Therapy

References